Presentations
Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia Presentation
Jun 29, 2021
Cerevel Therapeutics Corporate Presentation
May 17, 2021
$125M Non-Dilutive Financing for Tavapadon Presentation
Apr 13, 2021
Presentations at Movement Disorder Society Congress 2020: Analyses of Parkinson’s Disease Medication
Oct 01, 2020
View PDF 1.4 MB
Presentation at 2020 Epilepsy Foundation Pipeline Conference: CVL-865: The Journey to REALIZE
Aug 27, 2020